Last reviewed · How we verify
SASS
At a glance
| Generic name | SASS |
|---|---|
| Sponsor | CHU de Quebec-Universite Laval |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa (EARLY_PHASE1)
- GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment (PHASE1,PHASE2)
- Validation of a French Version of the DHEQ (NA)
- Symptom Management Implementation of Patient Reported Outcomes in Oncology (NA)
- SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma (PHASE1,PHASE2)
- Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy (NA)
- The Relationship Between Serum rT3 Concentrations, T3/T4 Ratio, and Symptoms/Quality of Life in Treated Hypothyroid Patients
- The Norwegian Sonothrombolysis in Acute Stroke Study Part 2 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SASS CI brief — competitive landscape report
- SASS updates RSS · CI watch RSS
- CHU de Quebec-Universite Laval portfolio CI